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Abstract This article examines the articulation and enactment of racialised classiﬁcations in
clinical practice guidelines and in accounts of clinical practice. It contributes to
debates about racialisation in medicine and its consequences. The research centred
on the case study of prescribing guidelines for hypertension in England and Wales,
drawing on documentary sources and semi-structured expert interviews. We found
that conceptual and socio-political uncertainties existed about how to interpret the
designation ‘Black patients’ and about the practices for identifying patients’ race/
ethnicity. To ‘close’ uncertainties, and thus produce the guidelines and treat
patients, respondents drew authority from disparate elements of the ‘topologies of
race’. This has implications for understanding processes of racialisation and for the
future use of racialised clinical practice guidelines. We argue that clinical practice
guidelines play a ‘nodal’ role in racialisation by forming an authoritative material
connection that creates a path for translating racialised research into racialised
healthcare practice, and that they carry with them implicit conceptual and socio-
political uncertainties that are liable to create inconsistencies in healthcare practice.
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Introduction
In certain contexts, clinicians in England and Wales are now guided to prescribe medicine
based on a judgement about the patient’s race/ethnicity.1 This practice raises sociological and
normative questions, as racialised categorisations are socially sensitive and scientiﬁcally con-
tentious. Current sociological interest in race/ethnicity and biomedicine is bringing together
two overlapping bodies of scholarship. Work at the intersection of science and technology
studies (STS) and the sociology of race/ethnicity has looked at the way racial/ethnic categories
are instantiated in biomedical research, and in particular through their inclusion in genomic
research. At the same time, sociologists of health and illness have a long-standing engagement
with race/ethnicity, including concerns about the causes and manifestations of ethnic inequali-
ties in health, and the difﬁculties that can arise from intervening in these. Through our research
on the development and practices of ‘racialised prescribing’, we contribute to this scholarship,
and speciﬁcally to debates about the risks and beneﬁts of using racialised classiﬁcations in
medicine and to sociological knowledge about the role of health care in articulating and enact-
ing racialised categories.
© 2018 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
Sociology of Health & Illness Vol. xx No. xx 2018 ISSN 0141-9889, pp. 1–16
doi: 10.1111/1467-9566.12727
While there is a growing body of biomedical research that differentiates patients and/or par-
ticipants racially, and an accompanying growth in social science examinations of these, there
has been little examination of whether or how these matters are translating into clinical prac-
tice. In this article we examine a case study of clinical practice guidelines (CPG) for hyperten-
sion in England and Wales that recommend racialised distinctions in prescribing. We report on
our analysis of documents (including guidelines, the studies cited in those guidelines and
stakeholder consultations) and semi-structured interviews with experts. This allows us to
address questions about the development and usage of a CPG that asks clinicians to make
racial/ethnic differentiations in their practice. To analyse our data we apply, for the ﬁrst time
in a clinical context, a ‘topological account of race’ (M’charek 2014: 48). This helps us to
explain how conceptual and socio-political uncertainties are ‘closed’ to allow the guideline to
be produced and implemented, and allows us to develop ideas about racialisation processes.
Background
Against a backdrop of policies that require health service providers to recognise and address
health inequalities, the UK has long-standing racial/ethnic variations in health (Nazroo 2010).
In the context of our research, there is reasonably consistent evidence of higher blood pressure
and an increased prevalence of hypertension among people from a range of minority ethnic
groups (Agyemang and Bhophal 2003, Lane and Lip 2001). Those in the Black African and
Black Caribbean ethnic groups, and women who identify as Bangladeshi, have been shown to
have the most elevated risk (Sproston and Mindell 2006). Variations in health outcomes as a
result of hypertension are also linked to race/ethnicity, including increased likelihoods of
stroke in Black British patients, heart disease in British Asian patients and chronic kidney dis-
ease in both Black British and British Asian patients (Brown 2006).
Sociologists of health have long engaged with conceptual questions about race/ethnicity,
alongside examining patterns of inequalities, racism, patient experience, and frameworks for
policy and practice (Ahmad and Bradby 2007, Nazroo 1998). Debates about whether race/eth-
nicity should be conceptualised in biological, social or cultural terms (or as some hybrid of
these) gain a hard, practical edge when the answers have implication for clinical practice
(Braun et al. 2007), biomedical research priorities (e.g. Montoya 2011) or how to measure and
address health inequalities (Aspinall 2001, Bradby 1995, 2003). One underlying issue is that
the beneﬁts of addressing racial/ethnic inequalities are attended by a risk of reifying ideas
about ﬁxed, homogenous and ‘othered’ groups. This raises fears about medical errors due to
misjudgements about race/ethnicity, and concern that differentiated health interventions will
contribute to essentialised ideas about group difference (Braun et al. 2007, Duster 2015). The
paradox of race as simultaneously oppressive and emancipatory has deep historical roots
(Schramm 2015). It ﬁnds contemporary expression in the biopolitics of ‘inclusion and
difference’ (Epstein 2008), where a conjunction of the state’s responsibility to deliver health-
care equality with scientiﬁc endeavours to understand population-level variation has aligned
socio-political classiﬁcations with biomedical research and created particular problematisations
of populations at risk. It has been argued that there is a tendency to naturalise socio-political
groups and, in an era dominated by genomic science, to biologise (or geneticise) the causes of
health differences between those groups (e.g. Duster 2015).
One preoccupation of those examining how genomics intersects with race/ethnicity has been
differences between contemporary and historical racialised science; asking whether we are wit-
nessing an entrenchment of old ideas (e.g. Duster 2015, Skinner 2007). One contemporary
inﬂection, revealed by empirical studies, is the interweaving of equality discourses into some
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genomic research (e.g. Fullwiley 2008, Montoya 2011); Bliss (2012), for example, argues that
an ‘anti-racist racialism’ is advanced when scientists use racial categories to unsettle biological
narratives of race or to address ethnic health inequalities. However, such studies also demon-
strate how racialised thinking shapes genomic knowledge production, and the authors express
unease about the geneticisation of racial/ethnic categories and the social consequences of this.
These ambiguities are not unique to genomics: similar debates accompany the ‘ritual’ use of
race/ethnicity as a variable in epidemiological research (Shim 2014), and they framed discus-
sion when a heart failure drug – BiDil – was licensed for ‘self-identiﬁed Black patients’ in the
US (Kahn 2012). This case sparked acrimonious debate about balancing concerns about the
reiﬁcation of race/ethnicity with contemporary opportunities for addressing health inequalities
(Pollock 2012).
Research about how this emerging science translates into clinical practice is sparse, but it
appears that practitioners also face conceptual and socio-political uncertainties. Bonham et al.
(2009) found US clinicians were wary of making simplistic connections between genes, race/
ethnicity and health; while in contrast, Hunt et al. (2013: 267) reported clinicians often
‘painted minority patients with a broad brush, drawing on a variety of presumptions’. Both
Bonham and colleagues and Hunt and colleagues found that US clinicians thought that race/
ethnicity is relevant in the clinic, but there was a lack of agreement about what this meant for
practice. In England, Dyson et al. (2007) document how the assumptions and understandings
of health practitioners and clients inﬂuenced constructions of ethnicity in a genetic screening
programme for sickle cell/thalassaemia. For example, some midwives appeared to have a belief
in distinct racial groups and others over-rode a standardised procedure for coding ethnicity by
assigning patient ethnicity based on visual cues like skin colour. We contribute to the above
body of scholarship by linking racialised research, CPGs and clinical practices, using the case
of hypertension.
Pollock (2012) shows that high blood pressure is a racialised disease category in the US,
and furthermore, she argues that being able to take action in the clinic involves ‘closing’
intractable problems about the nature and role of race. She argues that ‘African American
Hypertension’ is characterised by ‘epistemological eclecticism’ (Pollock 2012: 2) that reﬂects
the variety of aetiological factors for which race stands as a proxy (including variations linked
to socioeconomic status, poverty, diet, lifestyle, culture, stress, racism, biology or genetics).
Pollock explains that it is even less tenable for physicians than epidemiologists to separate
these factors. Thus, a common rhetorical move ‘in the ﬁeld of race and medicine’ involves
opening up the difﬁcult conceptual and/or socio-political questions about race, only to then
‘close the conversation to allow implementation of operational answers’ (Pollock 2012: 84).
This opening and ‘closing to operationalise’ reﬂects the fact that while clinical medicine is
concerned to understand the causes and distribution of disease it also ‘strives to determine the
course of action to be pursued at the patient’s bedside’ (Pollock 2012:84). The process of clos-
ing is a necessary step that facilitates action in the face of a perceived problem.
Given these contexts, biomedical science has become a key site for examining racialisation
to better understand its processes, dynamics and consequences (M’charek et al. 2014b, Duster
2015). Attending to racialisation involves analysing the social processes through which ideas
of racial/ethnic difference gain meaning or salience (e.g. Omi and Winnant 1994). We adopt a
‘topological approach’ that enables us to focus on questions about how racialised populations
are materialised (M’charek et al. 2014b). M’charek (2014) argues that race is enacted in
objects and practices rather than being ﬁxed in biology or ideology. From this perspective,
‘race gets assembled in speciﬁc historical contexts by associating different kinds of entities’
(M’charek et al. 2014a: 461). Assembling or enacting race involves folding together elements
– ideas, practices, artefacts and social relations – that can be spatially and/or temporally distant
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(M’charek 2014, M’charek et al. 2014a, 2014b, Schramm 2015). Consequently, race ‘moves
and changes shape depending on the times and places that are drawn together’ (M’charek
2014: 48). Using this approach it becomes possible to examine how race is ‘made up’ in
speciﬁc contexts, and to map ‘the epistemic genealogies and multiple references’ that enable it
to be meaningfully assembled (Schramm 2015: 53). We show the elements of race that are
enfolded in the creation and use of the CPG for hypertension.
To summarise so far, while ethnic health inequalities are well documented, the relationship
between race/ethnicity and health is rife with uncertainties and differentiated health care carries
a risk of reiﬁcation. Biomedicine is thus an important and useful site for considering racialisa-
tion and its consequences. Despite much recent work on constructions of race/ethnicity in
genomic research, relatively little attention has fallen on clinical practice. To address this gap
we focus on a CPG for hypertension in England and Wales, which, as we explain in the fol-
lowing section, has introduced racial/ethnic differentiation in prescribing pathways. When we
discuss our data, we reﬂect on how uncertainties about race/ethnicity in the guidelines were
‘closed’ to enable action, and how the disparate elements that get assembled in and around the
guidelines lent authority to these closures. We show that our novel adoption of a ‘topological
account of race’ (M’charek 2014: 48) can help to explain the articulations of racial/ethnic dif-
ference that occur in a clinical context, and use this analysis to suggest that authoritative arte-
facts like CPGs play a ‘nodal’ role in racialisation processes.
Methods
Our case study examines the development and implementation of guidelines for the treatment
of hypertension. In 2006, the National Institute for Health and Care Excellence (NICE), the
key provider of CPGs in England and Wales, updated its guideline on hypertension, introduc-
ing a prescribing algorithm differentiated by age and race/ethnicity (NICE 2006). This
approach was maintained in slightly amended form in the revised 2011 guideline (NICE
2011). The prescribing algorithm introduced in 2006 recommended that, as a ﬁrst line treat-
ment, people ‘55 years or older or Black patients of any age’ should be prescribed either a cal-
cium channel blocker or a diuretic, whereas, ‘people younger than 55 years’ should be
prescribed an ACE inhibitor or an angiotensin receptor blocker (ARB) (NICE 2006: 45).
Health professionals are ‘actively encouraged’ to follow such clinical guidelines, although
these are recommendations not obligations, and are not intended to replace ‘clinical expertise
and professional judgement’ (NICE 2017). In line with NICE’s standard process, an expert
Guideline Development Group developed the hypertension guidelines. Such groups draw on
commissioned reviews of evidence to produce evidence-based recommendations for practice.
In the NICE (2006) hypertension guideline, the prescribing algorithm was derived from clini-
cal trials evidence that was interpreted to show that different drugs could be more effective in
different sub-populations, and from evidence from other types of studies that was used to
explain these differences in effectiveness by combining ideas about drug mechanisms and
racially/ethnically differentiated disease pathologies.
The wider aims of our research were to understand: what ideas about race/ethnicity under-
pinned the guidelines and what research informed them; what discussions or controversies, if
any, were associated with the development of the guidelines; and what experts thought about
the implementation of the guidelines in practice and any difﬁculties that might arise.
The research involved documentary analysis and expert interviews. Documents included: (i)
three iterations of the NICE hypertension guidelines (North of England Hypertension Guide-
line Development Group 2004, NICE 2006, 2011) and associated materials concerning their
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development and implementation available on the NICE website; (ii) biomedical and trials lit-
erature cited as evidence for the racial/ethnic differentiation within the guidelines (23 articles);
(iii) responses to the NICE stakeholder consultation on the draft guidance (NICE n.d.); and
(iv) discussions about the guidelines published in medical journals, in particular the rapid
responses to papers in the BMJ that accompanied the launch of the 2006 and 2011 guidelines.
We reviewed these documents paying particular attention to the ways race/ethnicity were
deﬁned and discussed and awareness or discussion of the sensitivities and uncertainties relating
to race/ethnicity.
We also undertook 11 semi-structured expert interviews. Our aim was to elaborate on our
understandings of the guideline development and any attendant discussions and controversies
that we had identiﬁed from the published literature. The interviews provide an opportunity to
supplement our documentary analysis with any tacit or unreported facets. Interviews were also
used to explore the nature of concerns that might exist about the implementation of the guide-
lines and how these might be resolved.
Participants were purposively selected to include a range of expert viewpoints. We
approached 24 potential interviewees, identiﬁed through membership of the Guideline Devel-
opment Groups, through having commented on the guidelines or published on race/ethnicity
and hypertension in the UK context in clinical journals, and through snowball sampling. We
were careful to include experts from a range of disciplinary backgrounds, including clinical
expertise in cardiovascular disease, primary care, clinical pharmacology, public health and epi-
demiology. Nine interviewees were clinicians, three of whom had been members of a Guide-
line Development Group. We do not provide more speciﬁc details on the exact recruitment
and identity of different interviewees for the sake of anonymity. The research gained ethical
approval through institutional review at Bath Spa University.
Interviews were undertaken face-to-face (3) or by telephone (8) and lasted for 35–75 min-
utes. All were digitally recorded and transcribed. Interviews were semi-structured, guided by
an interview prompt that covered the same broad topics. They were tailored to the speciﬁc
contribution of different participants to either guideline development or public discussion of
this, and to their areas of expertise (including as clinicians, or not). In each case it covered
participants’ ideas about the basis for the differentiated prescribing pathway; whether they saw
any controversies or difﬁculties with the evidence or guidelines; how guidelines were, or
should be, applied in practice, including questions about how to judge patients’ race/ethnicity;
and whether they related this to wider questions about equality in health care. We recognise
that interview data do not provide a straightforward ‘window’ onto the enactment of the CPGs
in practice, but they do reveal these experts’ accounts of their practices, or for the non-clini-
cians, their opinions about clinical practices.
Interview data was analysed following a ‘framework’ approach (Ritchie and Spencer 1994),
whereby both authors reviewed transcripts to identify key themes, which were then applied
cross-sectionally to compare differences between respondents. In the analysis presented in this
article we concentrate on the different articulations and enactments of race/ethnicity that
emerge across the data as we moved from evidence to written guidance through consultation
to expert accounts of how these would or should be implemented in practice.
Findings
Our analysis focuses on: (i) the articulation of race/ethnicity in the CPGs and the discussions
surrounding these; and (ii) the enactments of race/ethnicity in interviewees’ reﬂections on and
accounts of clinical practice. We highlight for later discussion the disparate elements of the
© 2018 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL.
Racialised prescribing 5
topologies of race that get assembled to articulate and enact race/ethnicity, and the sources of
authority that are invoked to ‘close’ the conceptual and socio-political uncertainties that
emerge.
Articulation in the guideline: a science-state hybrid
A systematic search for scientiﬁc evidence of treatment efﬁcacy and a formalised stakeholder
consultation are central to the process for developing NICE guidelines (McManus et al. 2012).
When the draft of NICE guideline CG34 was circulated for consultation, it recommended a
differentiated prescribing pathway for ‘patients aged 55 or over, or Black patients of any age’.
We show: (i) that this recommendation was underpinned by clinical trials evidence from the
US; (ii) that when some stakeholders struggled to interpret the designation ‘Black patients’
used in that evidence, NICE initially closed uncertainty by invoking a bureaucratic requirement
to use an ethnic taxonomy from the census of England and Wales; (iii) that the articulation of
race/ethnicity in the ﬁnal guideline folds together these elements into a hybrid designation of a
racialised ‘target’ for prescribing practice.
To understand these articulations of race/ethnicity, it is useful to reﬂect on the origins of the
designation ‘Black patients’ in the draft guideline and how this relates to an apparently deci-
sive set of scientiﬁc evidence. While a racialised science of hypertension reaches back to the
1930s (Jamerson and DeQuattro 1996), the NICE (2006) guideline cited the 1994–2002 Anti-
hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to show
evidence of racial differences in clinical outcomes. ALLHAT was a US clinical trial that com-
pared the effectiveness of different antihypertensive drug regimens (The ALLHAT Ofﬁcers
and Coordinators for the ALLHAT Collaborative Research Group 2002). In an effort to
address questions about race-based health inequalities, this state-funded study recruited large
numbers of participants from minority ethnic groups. In ALLHAT’s protocol, a participant’s
race was deﬁned by self-report as Black, White, Asian, native American, and other (Wright
et al. 2005). In key publications, however, the last 4 categories are combined so that ﬁndings
are presented as a comparison of Black patients versus non-Black patients (Wright et al.
2005). As NICE guideline CG34 cites evidence from ALLHAT to support its racialised
approach, the designation ‘Black patients’ appears linked to these citations.
A number of aspects of the topologies of race can be illustrated here. ALLHAT’s deliberate
over-sampling of participants from minority ethnic groups illustrates that socio-political con-
cerns have been folded into the practice and outcomes of science, exemplifying Epstein’s
(2008) ‘inclusion and difference’ paradigm. The use of US clinical trials evidence in the NICE
guidelines exempliﬁes how elements, such as the designation ‘Black patients’, are drawn from
place to place (from the US to England and Wales), and from context to context (research
studies to clinical practice).
When the draft guideline was circulated in a consultation exercise, however, a wide range
of stakeholder organisations made comments about its use of race/ethnicity, including national
clinical professional organisations (Royal College of General Practitioners (RCGP), Royal Col-
lege of Nursing (RCN), Faculty of Public Health), health charities/ interest groups (Blood
Pressure Association (BPA), Diabetes UK, South Asian Health Foundation), academic experts
(University of Birmingham, Department of Primary Care & General Practice), industry (Merck
Sharp & Dohme Ltd) and healthcare providers (North Shefﬁeld Primary Care Trust (PCT),
Rotherham PCT). The most frequently expressed issue (seven instances) related to the clarity,
deﬁnition or meaning of the designation ‘Black patients’. For example, the BPA asked: ‘who
falls into the category of Black’ and the RCN questioned: ‘is it restricted to patients who are
African, Afro Caribbean, or to patients who are of mixed race origin?’ (NICE n.d.). These
question show that stakeholders’ were grappling with the implication that ‘Black patients’ was
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a concept that would need to be interpreted and operationalised in practice, although it is also
notable that these comments are not directly about the clinical validity of racialised prescribing
per se.
This focus on practicality was also accompanied by expressions of broader socio-political
and ethical concerns, including questions about how to treat other minority ethnic groups. Six
out of the seven questions about ‘who counts as Black’ were accompanied by a question about
how to treat ‘South Asians’. The term ‘South Asian’ is used in the UK, not least in health
research, as a pan-ethnic category encompassing those with Bangladeshi, Indian or Pakistani
origins (among others). Indeed, one of the stakeholder organisations that raised this question
exists to promote ‘good health in the UK’s South Asian communities’ (www.sahf.ord.uk).
Concerns about clarity for clinical practice thus overlap with issues of equality, inclusion and
representation. As such, some stakeholders argued that speciﬁc minority ethnic groups should
be named in the guideline, even, as the RCGP suggested, when ‘such mention may merely be
to state that evidence is lacking’. Another socio-political concern (raised twice) was sensitivity
to terminology; as the BPA noted: ‘The word Black may also be viewed by some as an offen-
sive or insensitive term’ (NICE n.d.).
Our expert interviews also provided evidence of similar socio-political sensitivities. For
example, two respondents thought that racial/ethnic difference was a sensitive or ‘taboo’
(Respondent 10) topic for research, and that this contributed to a lack of funding. Four inter-
viewees advocated ideas that promoted racial/ethnic equality, although there were differences
in their viewpoints about whether this meant paying more or less attention to race/ethnicity.
One feared that by ‘categorising people along [racial/ethnic] lines you create social division
and that probably will also lead to discriminatory, you know discrimination’ (Respondent 4);
but another argued against being worried about the use of race/ethnicity because: ‘you can
build in institutionalised or structural racism by reifying out diversity and saying everybody is
the same’ (Respondent 5).
In its documented reply to the stakeholder consultation, NICE accepted responsibility for
clarifying its terminology. Collating the various comments under a ‘combined response to
duplicate questions’, its summary of the key questions and its response to these read:
Should the guideline explain which patients are Black and which are not? Should the term
be used at all? It is NICE policy to use the ethnic taxonomy used by National Statistics in the
census. However, as various stakeholders have expressed concern about how to interpret this,
the developers have added a footnote to 1.5.1.1: “Including both Black African and Black Car-
ibbean patients, but not Asian, Chinese or other ethnic groups”. (NICE n.d.: 126)
Stakeholders’ conceptual/operational and socio-political concerns were thus addressed by
deferring to a policy of using an ethnic taxonomy from state bureaucracy and by specifying
certain categories. We do not know whether this response addressed the concerns of stakehold-
ers, but it does raise other awkward questions about clinical validity. For example, is it legiti-
mate to treat those who self-identify to the census categories ‘Black African’ and ‘Black
Caribbean’ in England and Wales as if they were the same as the ‘Black patients’ in the US
clinical trial?
The published guideline did not, in the end, actually use the above-noted census categories
(Black African and Black Caribbean) but instead created a ‘hybrid’ phrasing that speciﬁed the
population to be targeted: ‘Black patients are those of African or Caribbean descent, but not
mixed-race, Asian or Chinese patients’ (NICE 2006: 45). This is a notable departure from the
NICE policy stated in the stakeholder response document that raises two issues that we discuss
further in the next section. First it added ‘mixed-race’ as a speciﬁcally excluded patient popu-
lation, and second, it introduced the notion of ‘descent’.
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When we asked those who had been involved in guideline development whether race/ethnic-
ity was controversial in this process, they recalled issues of terminology but did not consider
these a signiﬁcant concern. When prompted to comment on how these issues were resolved,
one respondent appeared exasperated by the wrangling over language. He remembered ‘almost
losing the will to live’ when it was discussed, as ‘everybody knew what we were talking
about’ (Respondent 1). Another respondent appeared more disengaged and claimed a profes-
sional delineation: ‘the committee had made the decision and how that actually got represented
was something that could be hammered out by the draughtsmen’ (Respondent 2). However, as
he then went on to explain: ‘NICE wanted to be sure that the wording matched the evidence
and was politically correct’. We interpret the usage of the term ‘politically correct’ in this con-
text to be somewhat disparaging, signaling that group labels were a politicised and bureaucrati-
cally imposed concern that was separable from the scientiﬁc evidence. For these Guideline
Development Group members, the issue of racial/ethnic nomenclature appears to have been
both uninteresting and a source of frustration or annoyance. Their responses suggest percep-
tions of an overbearing socio-political or bureaucratic concern with terminology, which had to
be appeased. This discordance arises, we suggest, because the actors involved invoke their
authority for ‘closing’ the uncertainties of race/ethnicity from different realms: from science or
from state bureaucracy.
It is notable, however, that folded into scientiﬁc and bureaucratic standpoints, and more
broadly in stakeholder responses, were ‘common-sense’ notions of racial/ethnic difference: dif-
ference that is deemed manifest, obvious and uncontroversial (Posel 2001a, 2001b). The draft
guideline had labelled ‘Black patients’ as if this category was self-evident, an assumed conso-
nance that was encapsulated in the remark: ‘everybody knew what we were talking about’.
Furthermore, state classiﬁcations ‘perpetuate “conventions” of race already ingrained in the
social fabric’ (Posel 2001a: 104). In our case, the census categories adopted by NICE are
themselves contingent on British colonial history and are not part of the everyday or bureau-
cratic lexicon of racial/ethnic difference elsewhere in the world. Similarly, while the designa-
tion ‘South Asian’ is not a census category, it was part of the locally meaningful working
vocabulary of UK health organisations, which included an interest group that represents the
needs of that named population.
The articulation of race/ethnicity in the ﬁnal guideline can be understood as a folding
together of such disparate elements from the topologies of race. Designating a racialised ‘tar-
get’ population in the guideline brought into proximity evidence from a US clinical trial and a
bureaucratic census tool for England and Wales. This happened via a guideline development
process in which stakeholders raised conceptual/operational and socio-political questions (but
not, overtly at least, questions about clinical validity). The resulting articulation of race/ethnic-
ity in the guideline is a hybrid that folds together elements of race/ethnicity that originate from
various times and places. However, the discordance noted by respondents involved in guide-
line development highlights that claims to speak authoritatively about race/ethnicity were being
negotiated, ostensibly between those representing science and those representing the state.
Nonetheless, these authoritative standpoints and their negotiations are themselves informed by
and interlaced with ‘common-sense’ ideas about racial/ethnic difference.
Classiﬁcation in practice: self-identity, phenotype and population prototypes
In our interviews we further explored the existence and nature of concerns about applying the
CPGs in practice (non-clinicians were asked to offer their view on potential concerns). In pre-
senting our ﬁndings we draw a contrast between how interviewees answered questions that
were framed openly and their responses to questions we posed about liminal cases that were
designed to unsettle or breach the classiﬁcation scheme in the guideline.
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We asked respondents how they identiﬁed a patient’s race/ethnicity in practice or, if they
were not clinicians, how they would advise clinicians to do so. They suggested two main
methods: (i) asking patients to self-identify their race/ethnicity; and (ii) visual identiﬁcations,
an approach described as ‘eyeballing’ (Respondent 5) or ‘how people look’ (Respondent 9).
None of the respondents suggested or implied that either identiﬁcation process was considered
problematic in practice, although socio-political sensitivities were evident. Some respondents
voiced a tacit understanding that visually identifying a patient’s race/ethnicity might not be
considered a socially or professionally appropriate strategy. For example, a non-clinician dis-
tinguished between what he thought should ideally happen (asking) and what he thought often
does happen (visual identiﬁcation). One clinician commented that it might be ‘a crude thing to
say, but most of the time I guess it’s quite clear’ (Respondent 7). While this could mean that
a visual classiﬁcation was rudimentary (i.e. that it is crude to claim that people can be identi-
ﬁed racially/ethnically based on their appearance), the expression that it was ‘a crude thing to
say’ implies that visually identifying race/ethnicity is in itself a coarse or vulgar activity.
Another clinician acknowledged the potential sensitivities, but argued that these were allevi-
ated by the context: ‘I suppose there’s always that political correctness thing isn’t it, are you
afraid to insult anybody, but I think in the sort of healthcare setting I think people are less
concerned about it because you have to get to the answer before you can treat people’
(Respondent 9).
In these data we can see different elements of the topologies of race being used to close
uncertainties about a patient’s race/ethnicity. There is a standardised technique drawn from the
national census, whereby respondents are requested to self-identify from a classiﬁcation
scheme that (ostensibly) marks socio-political identities. By using this practice, health profes-
sionals invoke the authority of state bureaucracy. Another element is the practice of observer-
assigning race/ethnicity based on phenotypical differentiations like skin colour, hair texture,
etc.. We argue that these visual judgments, about ‘how people look’, close uncertainties by
invoking authority from ‘common-sense’. This is not only because they adopt ideas about
racial/ethnic difference that are based on ‘social notions of phenotypical difference’ (M’charek
et al. 2014b: 13) but also because some respondents considered such judgments to be ‘obvi-
ous’ (Posel 2001a, 2001b).
To test the idea that, as one respondent expressed it, ‘most of the time’ racial/ethnic identiﬁ-
cations were ‘quite clear’, we asked interviewees to reﬂect on instances that might challenge
the boundaries of the category ‘Black patients’. In particular, how might ‘mixed-race’ and
North African patients be identiﬁed and treated? The issues pertaining to ‘mixed-race’ and
North African patients were rarely brought up by respondents, but once raised were readily
acknowledged as ‘difﬁcult’, or ‘interesting’ or ‘not straightforward’. We show that respondents
closed uncertainties about such cases by recourse to ideas about ‘pure’ populations – or ‘popu-
lation prototypes’ – that draw authority from both ‘common-sense’ and science.
Once the issue of ‘mixed-race’ was raised, some respondents warmed to it, and volunteered
examples of patients who might not easily ﬁt the guideline classiﬁcation. When asked about
applying the guidelines, two clinicians said they would treat ‘mixed-race’ patients as if they
were ‘Afro Caribbean’, thereby categorising them as ‘Black patients’. Such a decision actually
runs contrary to the prescribing recommendations of the NICE (2006) guideline. Underlining
her sense that this question called for an active judgment, one of these respondents said: ‘I
think probably I’d have to nail my colours to the mast one way or another and I would proba-
bly classify them as being Afro Caribbean for the purposes of prescribing’. However, she also
implied a stance of critical ﬂexibility by adding the caveat: ‘and then I would monitor the
effect of the treatment and see how they got on with it’ (Respondent 7).
© 2018 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL.
Racialised prescribing 9
These respondents address uncertainties about ‘mixed-race’ by deciding which ‘component’
in a combination should be prioritised. Interpreted topologically, this practice draws on ideas
about race and mixture that invoke historical populations of ‘origin’ (Fullwiley 2008). The
decision to classify a ‘mixed-race’ patient as a ‘Black patient’ appears reminiscent of the so-
called ‘one drop rule’ in the US, which refers to the practice of using any evidence of African
ancestry to categorise a person as ‘Black’ (Davis 1991). However, we should not overlook
other elements of the topologies of race in this data, such as the (prompted) recognition of dif-
ﬁculties of categorising ‘mixed-race’ patients and the desire to ‘monitor the effect of treat-
ment’. These suggest that simplistic racial typologies can be folded together with more critical
repertoires that question the validity of racial/ethnic categorisations, including for clinical
practice.
In contrast to ‘mixed-race’ patients, North African patients were not considered to be the
‘Black patients’ speciﬁed in the guidelines. Such judgments were sometimes based on visual
cues. One clinician off-handedly remarked that: ‘having been to Egypt on holiday, some of
these people look more Asian’ (Respondent 7). Another elaborated: ‘I wouldn’t treat them like
a Black, no absolutely not. So probably a lot of it is visual actually [. . .], It wouldn’t occur to
me to put somebody say Tunisian or Egyptian on you know the Afro Caribbean pathway’
(Respondent 9). In this extract classiﬁcation is reported as almost obvious or self-evident.
Other clinicians, however, used more scientiﬁc terminology: ‘North Africans in terms of
migration origin do not come into the same concept of African descent. We’re talking about
sub-Saharan Africans’ (Respondent 8). As such, practices could be legitimated by reference to
scientiﬁc evidence: ‘So Africa decision-making ought to be based on whether the person has,
are of, African decent, West African preferably because . . . although that Kenyan paper, and
probably the South African data supports a general sub-Saharan thing’ (Respondent 3).
As with the ‘mixed-race’ example, respondents closed uncertainties by drawing together
phenotypical distinctions and ideas about population prototypes that carry the authority of
‘common-sense’; in this instance it was to decide that North Africans were not ‘Black patients’
of African descent. This can be interpreted as ‘common sense’ not only because it was based
on visual cues, but also because the possibility of that allocation could be beyond everyday
thinking (Posel 2001a, 2001b), as reﬂected in the respondent’s comment that ‘it wouldn’t
occur to me’. However, there were also explanations of this allocation that invoked the author-
ity of science. Some respondents justiﬁed the population-level category ‘Sub-Saharan Africans’
by reference to the epidemiology of (racialised) hypertension (e.g. Opie and Seedat 2005), and
used terms like migration and descent from the ‘sciences of human origins’ (Schramm 2014:
3). Indeed, it is this articulation of racial/ethnic difference that underpinned the NICE (2006:
45) guideline’s ‘hybrid’ phrase: ‘Black patients are those of African or Caribbean descent’.
While ‘descent’ changed to ‘family origin’ in the guideline’s 2011 update, the connotations of
biological ancestry remain clear, and stand in contrast to the idea that census categories are
manifestations of social identity.
Discussion
Although the introduction of racialised categories in CPGs and clinical practice in this case
was considered to be relatively unproblematic by most respondents in most instances, concep-
tual and socio-political uncertainties about race/ethnicity were also apparent. In light of these
ﬁndings, we discuss two interlinked questions. First, how is race/ethnicity articulated and
enacted, including in the attitudes of our respondents? Second, how were inherent conceptual
and socio-political uncertainties ‘closed’ so that guidelines could be created and implemented?
© 2018 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL.
10 Andrew Smart and Kate Weiner
One discussion about the potential social harms of using race/ethnicity in medicine centres
on concerns about reifying racial/ethnic groups. Contemporary practices are contrasted with
historical racial science for their focus on ancestry (not race), clines of genetic variation (not
discrete racial categories) and ‘likelihoods’ of group differences (not essential characteristics)
(Fujimura and Rajagopalan 2011). Our data on uncertainties relating to liminal cases, espe-
cially the expression of an over-riding concern about monitoring treatment outcomes, lends
some support to the idea that clinicians recognise conceptual complexity (Bonham et al.
2009). However, some of the ways in which race/ethnicity was enacted among our sample
were decidedly ‘unreconstructed’: visual ascription (eyeballing), treating ‘mixed-race’ as
‘Black’, and (sometimes tacit) ideas of a prototypical sub-Saharan population type of true Afri-
cans. Other scholars have also noted these kinds of ad hoc judgments in assigning racial/ethnic
identities to patients (Braun et al. 2007, Dyson et al. 2007, Hunt et al. 2013) or research sub-
jects (Shim 2014). Most of our respondents thought that, in most cases, identifying race/ethnic-
ity was an unproblematic act, because they either requested their patients to self-identify to a
standard classiﬁcation, or they regarded their visual judgments as ‘common-sense’ (Posel
2001a, 2001b). Yet, we saw the potential for ‘mis-assignment’ (Braun et al. 2007, Dyson
et al. 2007, Hunt et al. 2013) within the parameters of the guideline’s classiﬁcation when it
came to the treatment of ‘mixed-race’ patients. For our respondents, treating some ‘mixed-
race’ patients on the ‘Black patient’ pathway did not appear to raise concerns about mistreat-
ment or error. However, even if the health risks are low in this clinical context (and this is not
something we are in position to judge), this still raises issues about the consistency of practice
when applying racialised guidelines, especially in relation to categories that may be ‘liminal’.
It has also been argued that contemporary racialised science is now, in part, informed by
concerns about inequality (e.g. Fullwiley 2008, Montoya 2011). In our study, an ‘equality and
diversity’ discourse was evident in the stakeholder consultation process. Furthermore, some
interviewees (usually but not exclusively experts in epidemiology and public health) were
overtly concerned by ethnic inequalities. While they advanced an ‘anti-racist racialism’ (Bliss
2012), this centred more on health inequalities and less on the deconstruction of biological
race, or the dangers of reiﬁcation (Duster 2015). Concerns about reifying race/ethnicity as bio-
logical or natural rarely ﬁgured as a proximate or tangible risk relating to guideline develop-
ment and never appeared in accounts of clinical decision-making. We also found notable
variations in how ideas about socio-political sensitivities were articulated, including anxieties
about saying ‘crude’ things and the dismissal or disparagement of a perceived imposition of
‘political correctness’. It is important to recognise the existence of both supportive and resis-
tant attitudes toward ‘equality and diversity’ policies and the ambiguities in their articulation,
as these could inﬂuence how racialised CPGs are perceived, understood or practiced.
Attending to the attitudes of professionals is important for understanding and shaping prac-
tice, and it also helps to demonstrate the novelty of contemporary contexts. However, a moti-
vations-based analysis risks pigeonholing ‘good’ and ‘bad’ scientists or clinicians based on
their values/attitudes. Furthermore, we might ask how much (analytical) weight should be
attached to equality-orientated attitudes when the racialising practices of overtly equality-
oriented scientists or clinicians are substantially the same as those of others? Motivations, then,
should be seen as only part of the analysis.
Our remaining analysis will focus on the social architectures that respondents drew upon to
articulate and enact race/ethnicity. To do this, we pursue Pollock’s (2012) claim that biomedi-
cal practitioners ‘close’ conceptual and socio-political uncertainties about race/ethnicity in
order to act in their professional capacities. This explanation is helpful, but it says relatively
little about how this practice is facilitated, or how judgments are shaped. Here we return to the
idea of the topologies of race, which works on ‘the presupposition that elements that are
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distant in time and space can become proximate and relevant in the here and now’ (M’charek
et al. 2014b: 5). Uncovering the connections between disparate elements is important as it not
only reduces the analytical emphasis on the motives of individuals, but also reveals how the
CPGs for hypertension are enfolded with wider social processes of racialisation.
What elements are made ‘proximate’ in this case? Temporally, the guideline enrols 80 years
of scientiﬁc thinking about racial/ethnic difference in hypertension, including theorising and
investigating at the genetic, molecular, biological, somatic and epidemiological levels. Spa-
tially, it aligns to research undertaken on racially/ethnically labelled populations from across
the world, including the important ALLHAT trial that was designed to reﬂect a US socio-poli-
tical agenda that demanded ‘inclusiveness’. During guideline development, other socio-political
inﬂuences were woven into the CPG such as NICE’s policy for using a national census tool; a
classiﬁcation which itself reﬂects locally situated ‘racial common-sense’ (Posel 2001a, 2001b)
and 30 years of contestation between state bureaucracy, minority ethnic groups and social sci-
entists (Booth 1985, Sillitoe and White 1992). The stakeholder engagement introduced other
context-speciﬁc issues, including conceptual/operational and socio-political concerns about
implementation. The articulation of race/ethnicity in the ﬁnal CPG folded together these vari-
ous elements, and coined the hybrid designation: ‘Black patients of African or Caribbean des-
cent’. When we asked how patients were (or should be) classiﬁed in order to implement the
guidelines, responses reﬂected logics and techniques that invoked state bureaucracy (to request
racial/ethnic self-identiﬁcation) and/or ‘common-sense’ and scientiﬁc notions of phenotype and
population prototypes (to observer-assign race/ethnicity).
We suggest that our respondents ‘closed’ the inherent conceptual and socio-political uncer-
tainties of racialised prescribing by folding together these disparate elements to justifying a
racialised approach. The elements of race that were articulated in our case study invoked
authority from different sources: science, state or ‘common-sense’. Yet it is the layering of these
that created a formidable racialised logic. If one source of authority failed, another was on hand:
if the science was vague, the state census was used; if the census classiﬁcations were not help-
ing, ‘common-sense’ was called upon. This layering of multiple sources of authority allowed
emergent problems in the classiﬁcation process to be ‘worked around’, and for racialised pre-
scribing for hypertension to be normalised (cf. Bowker and Star 1999, Posel 2001a, 2001b).
We can further consider the place of CPGs in sustaining the topologies of race. Schramm
(2015:53) directs our ‘attention to the nodes, holes and ﬁssures through which the multiple
connections between different sectors and their racialising effects become visible’. We argue
that the racialised hypertension guideline is one such node as, following Latour’s (1996) char-
acterisation of nodes as having multiple dimensions and connections, it draws together ele-
ments from science, the state and ‘common-sense’. Such nodes can be generative - points of
renewal and growth that reﬂect, entrench and create connections between ideas, practices, arte-
facts and social relations (Latour 1996). The guideline encourages racialisation as it is a mate-
rial connection that authoritatively created a path for translating racialised research into
racialised healthcare practice. Moreover, it generates fresh information ﬂows and feedback
loops (Hacking 1999) organised by racialised logic (clinical experiences, patient understand-
ings, prescribing patterns, etc.). Enacting a racialised CPG reproduces, sustains and perhaps
encourages particular ideas about racial/ethnic difference, and the populations deﬁned therein.
What are the particular ideas and relations of racial/ethnic difference that are made, or made
to ‘stick’ (M’charek 2014: 48) in our case? While we found some instances of nuanced think-
ing about race/ethnicity, it is largely essentialised notion of racial/ethnic difference that were
reproduced. The creation and implementation of the CPGs involves a conﬁrmation bias; selec-
tively enacting ideas and practices that support racialised logics, while ‘working around’ or
marginalising those that are contrary or critical. To this extent, using racial/ethnic categories in
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CPGs normalises racialised logics in medicine and healthcare practice, which may, in turn,
feed into other essentialist discourses on racial/ethnic difference in science and society.
Conclusion
We can use our study to propose some theoretical implications about racialisation in the con-
text of health. We echo M’charek et al.’s (2014b) topological account of race, where the justi-
ﬁcations for racialised thinking and action can be multiple, potentially intersecting, but not
necessarily coherent. However, we emphasise that a triumvirate of powerful authority sources
underpin the processes and logic of racialisation. Social actors can ‘close’ inherent conceptual
and socio-political uncertainties about race/ethnicity by overtly or tacitly invoking authority
from science, the state and/or ‘common-sense’. In the face of persistent uncertainty, ideas and
practices that draw authority from different sources may be layered up to reinforce one
another, or perhaps fused to create novel, hybridised articulations. Additionally, within this
‘live’ mesh of ideas and practices, certain artefacts act as nodes, or conduits, for perpetuating,
expanding or transforming racialised logics. In formal contexts, like health care, such artefacts
will be likely to claim the rationalist authority of science and/or the state (which is not to say
that they are divested of ‘common-sense’ ideas about racial/ethnic difference). We suggest that
such artefacts are important to explanations of racialisation as they shed light on the persis-
tence and the plasticity of ideas about racial/ethnic difference, and they perhaps offer a locus
for interventions that seek to control or change such ideas.
Judging if our ﬁndings are ‘transferable’ to other health contexts would require further data,
but we can tentatively suggest an implication of racialised CPGs. The goal of guidelines – to
standardise practice – will be difﬁcult to achieve because of the implicit conceptual and socio-
political uncertainties of race/ethnicity. Conceptual uncertainties give rise to operational difﬁ-
culties, which could include problems like: naming categories and deﬁning their boundaries;
designing effective and efﬁcacious classiﬁcation schemes; ensuring a ‘ﬁt’ between formalised
schemes and everyday practice; and, providing training and/or guidance to ensure formal
schemes are used consistently. Socio-political uncertainties leave space for beliefs and values
to enter into judgments. Whether practitioners think that it a ‘good thing’ or a ‘bad thing’ to
design or use racialised CPGs could be inﬂuenced by personal or political differences, such as:
perceptions and understandings of race/ethnicity; attitudes toward racial/ethnic inequalities; or,
opinions of ‘equality and diversity’ or ‘anti-racist’ agendas, policies or practices. It is clear that
some professionals who produce or follow racialised CPGs will perceive them as relatively
uncontroversial and intuitive. However, it seems inevitable that the implicit conceptual and
socio-political uncertainties of race/ethnicity will emerge, and when these are ‘closed’ to
enable action (Pollock 2012) there will be differences in practice. The health risks of such
variations or the inconsistent application of guidelines are likely to depend on clinical context.
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Note
1 Race and ethnicity are distinct but overlapping concepts. We adopt the term race/ethnicity to reﬂect
the blurriness of the concepts and language used in our study. When citing the work of others we
maintain their original terminology.
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